Improving Donor Liver Quality for Transplant
CEACAM1 Alternative Splicing in Liver Ischemia-Reperfusion Injury
This work explores how a specific protein in donor livers, called CEACAM1, can be adjusted to make livers healthier and more suitable for transplant.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Los Angeles NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project ID | NIH-11176131 on NIH RePORTER |
What this research studies
Our bodies have a protein called CEACAM1 in the liver, which plays a role in how well a liver recovers after being stressed, such as during organ donation and transplant. This project looks at different versions of the CEACAM1 protein, specifically a 'short' version (CC1-S) and a 'long' version (CC1-L), and how they affect liver health. We believe that the 'short' version helps protect liver cells, while the 'long' version helps manage inflammation after a transplant. By understanding and potentially controlling these protein versions, we hope to reduce damage to donor livers and improve outcomes for patients receiving a transplant.
Who could benefit from this research
Good fit: This research is most relevant to patients who are awaiting or have recently received a liver transplant, as it aims to improve the quality of donor organs.
Not a fit: Patients not in need of a liver transplant would not directly benefit from this specific research.
Why it matters
Potential benefit: If successful, this work could lead to more available donor livers and better recovery for patients undergoing liver transplantation.
How similar studies have performed: Previous findings have indicated that hepatic CEACAM1 influences donor liver quality and helps prevent early injury in both mice and humans.
Where this research is happening
Los Angeles, United States
- University of California Los Angeles — Los Angeles, United States (Active)
Researchers
- Principal investigator: Kupiec-Weglinski, Jerzy W — University of California Los Angeles
- Study coordinator: Kupiec-Weglinski, Jerzy W
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.